News Release

Printer Friendly Version View printer-friendly version
<< Back
Clearside Biomedical, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017 – Conference Call to Follow

ALPHARETTA, Ga., March 07, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) (“Clearside” or the “Company”), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its fourth quarter and full year 2016 financial results will be released at 7:00 a.m. on Tuesday, March 14, 2017. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a general business and strategic review.

The live webcast and a replay may be accessed by visiting the “Investor Relations” section at www.clearsidebio.com. Alternately, please call (844) 263-8310 (U.S.) or (213) 358-0959 (international) to participate in the live conference call. The conference ID number for the live call is 84209729. Please dial in approximately 10 minutes prior to the call. An archive of the webcast will be available until April 13, 2017.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and pre-clinical candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration.  To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.

Contacts:

Stephen Kilmer
Investor Relations
(678) 270-3631
stephen.kilmer@clearsidebio.com

Charles Deignan
Chief Financial Officer
678-270-4005
charlie.deignan@clearsidebio.com

Primary Logo

Clearside Biomedical, Inc.